hydroxychloroquine has been researched along with Polymyositis in 3 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Polymyositis: Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report one case of dermatomyositis and one case of polymyositis and scleroderma in which the patients' condition improved after treatment with cyclosporine (cyclosporine A)." | 7.68 | Cyclosporine treatment for dermatomyositis/polymyositis. ( Mehregan, DR; Su, WP, 1993) |
| "We report one case of dermatomyositis and one case of polymyositis and scleroderma in which the patients' condition improved after treatment with cyclosporine (cyclosporine A)." | 3.68 | Cyclosporine treatment for dermatomyositis/polymyositis. ( Mehregan, DR; Su, WP, 1993) |
| "Dermatomyositis is an idiopathic inflammatory myopathy with characteristic skin manifestations." | 2.41 | Dermatomyositis. ( Koler, RA; Montemarano, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Teh, CL | 1 |
| Wong, JS | 1 |
| Soo, HH | 1 |
| Mehregan, DR | 1 |
| Su, WP | 1 |
| Koler, RA | 1 |
| Montemarano, A | 1 |
1 review available for hydroxychloroquine and Polymyositis
| Article | Year |
|---|---|
Dermatomyositis.
Topics: Adult; Azathioprine; Child; Dermatologic Agents; Dermatomyositis; Diagnosis, Differential; Female; H | 2001 |
2 other studies available for hydroxychloroquine and Polymyositis
| Article | Year |
|---|---|
Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak General Hospital.
Topics: Aged; Antirheumatic Agents; Biopsy; Cross-Sectional Studies; Dermatomyositis; Electromyography; Fema | 2012 |
Cyclosporine treatment for dermatomyositis/polymyositis.
Topics: Azathioprine; Cyclosporine; Dermatomyositis; Female; Humans; Hydroxychloroquine; Middle Aged; Polymy | 1993 |